Fig. 3

Remibrutinib does not deplete B cells in HuMOG EAE, but shows trend for reduced Th17 T cell frequencies. Mice immunized with HumanMOG showed no significant changes in the frequencies of a CD19 B cells or b CD4 T cells analyzed in the total lymphocyte gate in spleen, blood or lymphnodes (LN). In contrast, c PMA/ionomycin induced intracellular IL-17 staining revealed a trend for reduced Th17 CD4 T cell frequencies with a p value of 0.057 and 0.072 for 3 and 30 mg/kg dose, respectively. (Mean ± , n = 5, two way ANOVA followed by Dunnett’s test.)